The treatment of depression with different formulations of venlafaxine: a comparative analysis.
Saved in:
| Title: | The treatment of depression with different formulations of venlafaxine: a comparative analysis. |
|---|---|
| Authors: | Olver, James S., Burrows, Graham D., Norman, Trevor R. |
| Source: | Human Psychopharmacology: Clinical & Experimental. Jan2004, Vol. 19 Issue 1, p9-16. 8p. 1 Diagram, 6 Charts. |
| Subjects: | Mental depression, Therapeutics, Venlafaxine, Nausea, Dizziness, Pharmacokinetics |
| Abstract: | Venlafaxine is the first of a group of antidepressants that show dual reuptake inhibition of serotonin and noradrenaline (SNRIs). Originally marketed in an immediate release (IR) formulation a microencapsulated, extended release (XR) formulation is now available. Significant differences exist between these two formulations with respect to pharmacokinetic parameters which have an impact on clinical use. The XR has lower maximum plasma concentrations (C [sub max] ) and achieves these at a later time (higher T [sub max] ). The longer apparent elimination half-life of the drug after single XR doses suggests that it is suitable for once daily dosing compared with the twice daily dosing regimen required by the IR formulation. With respect to antidepressant efficacy the XR formulation is equivalent to other marketed antidepressants and to the IR formulation. Consistent with its pharmacokinetic properties the use of the XR formulation is associated with less nausea and dizziness at the initiation of therapy. While in clinical usage XR might be expected to increase compliance with medication and to reduce discontinuation syndromes there are few comparative studies for which this has been evaluated. The XR formulation of venlafaxine is no worse than the IR form with respect to tolerability and offers some benefits to patients in terms of ease of use. On the other hand there does not appear to be any increase in the efficacy of the active agent. Copyright © 2004 John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR] |
| Copyright of Human Psychopharmacology: Clinical & Experimental is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: pbh DbLabel: Psychology and Behavioral Sciences Collection An: 11901348 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: The treatment of depression with different formulations of venlafaxine: a comparative analysis. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Olver%2C+James+S%2E%22">Olver, James S.</searchLink><br /><searchLink fieldCode="AR" term="%22Burrows%2C+Graham+D%2E%22">Burrows, Graham D.</searchLink><br /><searchLink fieldCode="AR" term="%22Norman%2C+Trevor+R%2E%22">Norman, Trevor R.</searchLink> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Human+Psychopharmacology%3A+Clinical+%26+Experimental%22">Human Psychopharmacology: Clinical & Experimental</searchLink>. Jan2004, Vol. 19 Issue 1, p9-16. 8p. 1 Diagram, 6 Charts. – Name: Subject Label: Subjects Group: Su Data: <searchLink fieldCode="DE" term="%22Mental+depression%22">Mental depression</searchLink><br /><searchLink fieldCode="DE" term="%22Therapeutics%22">Therapeutics</searchLink><br /><searchLink fieldCode="DE" term="%22Venlafaxine%22">Venlafaxine</searchLink><br /><searchLink fieldCode="DE" term="%22Nausea%22">Nausea</searchLink><br /><searchLink fieldCode="DE" term="%22Dizziness%22">Dizziness</searchLink><br /><searchLink fieldCode="DE" term="%22Pharmacokinetics%22">Pharmacokinetics</searchLink> – Name: Abstract Label: Abstract Group: Ab Data: Venlafaxine is the first of a group of antidepressants that show dual reuptake inhibition of serotonin and noradrenaline (SNRIs). Originally marketed in an immediate release (IR) formulation a microencapsulated, extended release (XR) formulation is now available. Significant differences exist between these two formulations with respect to pharmacokinetic parameters which have an impact on clinical use. The XR has lower maximum plasma concentrations (C [sub max] ) and achieves these at a later time (higher T [sub max] ). The longer apparent elimination half-life of the drug after single XR doses suggests that it is suitable for once daily dosing compared with the twice daily dosing regimen required by the IR formulation. With respect to antidepressant efficacy the XR formulation is equivalent to other marketed antidepressants and to the IR formulation. Consistent with its pharmacokinetic properties the use of the XR formulation is associated with less nausea and dizziness at the initiation of therapy. While in clinical usage XR might be expected to increase compliance with medication and to reduce discontinuation syndromes there are few comparative studies for which this has been evaluated. The XR formulation of venlafaxine is no worse than the IR form with respect to tolerability and offers some benefits to patients in terms of ease of use. On the other hand there does not appear to be any increase in the efficacy of the active agent. Copyright © 2004 John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR] – Name: AbstractSuppliedCopyright Label: Group: Ab Data: <i>Copyright of Human Psychopharmacology: Clinical & Experimental is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=11901348 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1002/hup.551 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 8 StartPage: 9 Subjects: – SubjectFull: Mental depression Type: general – SubjectFull: Therapeutics Type: general – SubjectFull: Venlafaxine Type: general – SubjectFull: Nausea Type: general – SubjectFull: Dizziness Type: general – SubjectFull: Pharmacokinetics Type: general Titles: – TitleFull: The treatment of depression with different formulations of venlafaxine: a comparative analysis. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Olver, James S. – PersonEntity: Name: NameFull: Burrows, Graham D. – PersonEntity: Name: NameFull: Norman, Trevor R. IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 01 Text: Jan2004 Type: published Y: 2004 Identifiers: – Type: issn-print Value: 08856222 Numbering: – Type: volume Value: 19 – Type: issue Value: 1 Titles: – TitleFull: Human Psychopharmacology: Clinical & Experimental Type: main |
| ResultId | 1 |
